share_log

EyePoint Pharmaceuticals | 8-K: Current report

EyePoint Pharmaceuticals | 8-K: Current report

EyePoint Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  10/31 16:21

Moomoo AI 已提取核心訊息

EyePoint Pharmaceuticals, Inc., a biopharmaceutical company focused on retinal diseases, has successfully closed an underwritten public offering on October 31, 2024. The offering involved the sale of 12,727,273 shares of common stock at a price of $11.00 per share, along with an additional 1,909,090 shares following the full exercise of the underwriters' option to purchase additional shares at the same price. The underwriting agreement was entered into with J.P. Morgan Securities LLC, acting as the representative of the underwriters. The net proceeds from the offering amounted to approximately $151.1 million after deducting underwriting discounts, commissions, and other estimated offering expenses. EyePoint Pharmaceuticals intends to use the proceeds to advance the clinical development of DURAVYU™ for wet age-related macular degeneration and diabetic macular edema, support earlier stage pipeline initiatives, and for general corporate purposes. The offering was made pursuant to the company's shelf registration statement on Form S-3, declared effective by the SEC on August 16, 2024.
EyePoint Pharmaceuticals, Inc., a biopharmaceutical company focused on retinal diseases, has successfully closed an underwritten public offering on October 31, 2024. The offering involved the sale of 12,727,273 shares of common stock at a price of $11.00 per share, along with an additional 1,909,090 shares following the full exercise of the underwriters' option to purchase additional shares at the same price. The underwriting agreement was entered into with J.P. Morgan Securities LLC, acting as the representative of the underwriters. The net proceeds from the offering amounted to approximately $151.1 million after deducting underwriting discounts, commissions, and other estimated offering expenses. EyePoint Pharmaceuticals intends to use the proceeds to advance the clinical development of DURAVYU™ for wet age-related macular degeneration and diabetic macular edema, support earlier stage pipeline initiatives, and for general corporate purposes. The offering was made pursuant to the company's shelf registration statement on Form S-3, declared effective by the SEC on August 16, 2024.
eyepoint pharmaceuticals，一家專注於視網膜疾病的生物製藥公司，已於2024年10月31日成功完成了承銷的公開發行。該發行涉及以每股11.00美元的價格出售了12,727,273股普通股，以及在行使承銷商購買額外股份的全部權利後，額外出售了1,909,090股股票。承銷協議是與摩根大通證券有限責任公司簽訂的，後者充當承銷商代表。扣除承銷折讓、佣金和其他預估的發行費用後，該發行所得淨額約爲15110萬美元。眼點製藥打算使用這筆款項推動DURAVYU™在濕性老年性黃斑變性和糖尿病性黃斑水腫的臨床研發，並支持較早階段的產品管線計劃，以及用於一般公司用途。該發行是根據公司在2024年8月16日由美國證券交易委員會宣佈生效的S-3表格的備案註冊聲明進行的。
eyepoint pharmaceuticals，一家專注於視網膜疾病的生物製藥公司，已於2024年10月31日成功完成了承銷的公開發行。該發行涉及以每股11.00美元的價格出售了12,727,273股普通股，以及在行使承銷商購買額外股份的全部權利後，額外出售了1,909,090股股票。承銷協議是與摩根大通證券有限責任公司簽訂的，後者充當承銷商代表。扣除承銷折讓、佣金和其他預估的發行費用後，該發行所得淨額約爲15110萬美元。眼點製藥打算使用這筆款項推動DURAVYU™在濕性老年性黃斑變性和糖尿病性黃斑水腫的臨床研發，並支持較早階段的產品管線計劃，以及用於一般公司用途。該發行是根據公司在2024年8月16日由美國證券交易委員會宣佈生效的S-3表格的備案註冊聲明進行的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間